Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Mar 01, 2017 Theratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for its Fiscal Year 2017 Mar 01, 2017 Theratechnologies to Host Investment Community Webcast on March 1, 2017 Feb 24, 2017 Theratechnologies to Host Investment Community Webcast on March 1, 2017 Feb 15, 2017 Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab Feb 14, 2017 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab Feb 08, 2017 Theratechnologies Announces Financial Results for Fiscal Year 2016 Dec 05, 2016 Theratechnologies closes its offering of common shares Nov 25, 2016 Theratechnologies Announces the Filing of a Final Short Form Prospectus Nov 14, 2016 Theratechnologies Announces $16.5 Million Bought Deal Financing Nov 10, 2016 Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab First page « Previous page ‹ … Page 26 Page 27 Page 28 Page 29 Current page 30 Page 31 Page 32 Page 33 Page 34 … Next page › Last page » Displaying 291 - 300 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Mar 01, 2017 Theratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for its Fiscal Year 2017
Feb 15, 2017 Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Feb 14, 2017 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
Nov 10, 2016 Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab
